Net Present Value Model: Xarelto
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Xarelto Drug Details
Rivaroxaban (Xarelto) belongs to the class of antithrombotic agents. It is formulated as film-coated tablets, tablets, granules/powder for suspension and suspension for oral route of administration. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. Rivaroxaban is indicated for the treatment of adults, to prevent venous thromboembolism (VTE, the formation of clots in the veins) in patients who are undergoing surgery to replace a hip or knee; to prevent stroke caused by a blood clot in the brain and systemic embolism (a blood clot in a blood vessel) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart); and to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg), and to prevent DVT re-occurring and pulmonary embolism (a clot in a blood vessel supplying the lungs) following a severe case of DVT. Xarelto is also indicated for the treatment of pulmonary thromboembolism and deep vein thrombosis. Xarelto film-coated tablet (2.5 mg), in combination with 75 mg -100 mg acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with symptomatic peripheral artery disease (PAD) at demonstrated high risk of major adverse limb events (MALE) or major adverse cardiovascular and cerebrovascular events (MACCE). Xarelto is indicated for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure, venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment.Rivaroxaban (Xarelto) is under development for the treatment of acute venous thromboembolism in pediatric and adult patients, coronary artery disease and high risk of thromboembolic disease in moderate to severe coronavirus disease 2019 (COVID-19).It was also under development for the prevention of major adverse cardiac events (MACE) in patients with chronic heart failure and significant coronary artery disease, heparin-induced thrombocytopenia (HIT), prevention of stroke in patients who have experienced embolic stroke of undetermined source (ESUS) and myocardial infarction.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports

